Used primarily in pharmaceutical research and development, this compound serves as a key intermediate in the synthesis of bioactive molecules, particularly kinase inhibitors. Its structural features enable strong binding interactions with specific enzyme targets, making it valuable in the design of drugs for inflammatory diseases and certain cancers. The trifluoromethylphenyl and pyrazolopyrimidine moieties contribute to enhanced metabolic stability and target selectivity. Due to its trans-configuration and steric properties, it influences the potency and pharmacokinetic profile of the final drug substance. It is not used as a standalone therapeutic but plays a critical role in optimizing lead compounds during preclinical stages.